BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Chardan Research initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) on Wednesday, citing the potential of its epilepsy franchise. Analyst Rudy Li writes, “Epilepsy remains one of our ...
Praxis Precision Medicines, Inc. announced significant advancements in its clinical portfolio, highlighting three late-stage assets poised for potential blockbuster status and the expectation of four ...
Praxis Precision Medicines, Inc. announced significant progress in its clinical pipeline, projecting six major study readouts across four programs in the next 12 months. The company plans to initiate ...
Ulixacaltamide’s Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by ...
Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. After brushing off a recommendation to end a phase 3 study earlier this year based on ...
The last time I spoke about Praxis Precision Medicines, Inc. (PRAX), it was in a Seeking Alpha article entitled "Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide." At that ...
On Friday, Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released interim data from Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET). The Independent Data Monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results